A Therapy for Most with Cystic Fibrosis.

Abstract excerpt

TRIKAFTA is the third drug approved by the FDA that rescues defects caused by the major mutation F508del. It is superior to its predecessors that were approved for patients who are homozygous for F508del because TRIKAFTA is also effective in CF patients who harbor only one copy of this mutation.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminophenols
• Share to Benzodioxoles
• Share to Cystic Fibrosis Transmembrane Conductance Regulator